Contact
searchSearch
HMP Global
Login

HER2 News

FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Novel Antibody-Drug Conjugate Showed Promise Among Patients With Advanced Breast Cancer With Low HER2 Expression
09/25/2025
Allison Casey
In a phase 2 study, MRG002 demonstrated manageable safety profile and promising anti-tumor activity among patients with locally advanced or metastatic breast cancer with low HER2 expression.
In a phase 2 study, MRG002 demonstrated manageable safety profile and promising anti-tumor activity among patients with locally advanced or metastatic breast cancer with low HER2 expression.
In a phase 2 study, MRG002...
09/25/2025
Oncology
News
Sequential HER2-Targeted Therapy Following Trastuzumab Deruxtecan Discontinuation Among Patients With HER2-Positive Metastatic Breast Cancer
09/12/2025
Stephanie Holland
Sequential HER2-targeted therapy following trastuzumab deruxtecan discontinuation demonstrated clinical promise among patients with HER2-positive metastatic breast cancer who responded to T-DXd however discontinued treatment due to adverse...
Sequential HER2-targeted therapy following trastuzumab deruxtecan discontinuation demonstrated clinical promise among patients with HER2-positive metastatic breast cancer who responded to T-DXd however discontinued treatment due to adverse...
Sequential HER2-targeted therapy...
09/12/2025
Oncology
News
Promising Intracranial Activity With Trastuzumab Deruxtecan Among Patients With HER2-Positive/Low Metastatic Breast Cancer With Active Brain Metastases
08/07/2025
Allison Casey
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
According to real-world data,...
08/07/2025
Oncology
News
Broader Use of HER2-Based Targeted Therapies Significantly Improves Long-Term Survival in De Novo HER2-Positive Metastatic Breast Cancer
07/08/2025
Stephanie Holland
Results from a real-world, population-based study demonstrated that broader use of HER2-targeted systemic therapies significantly improved long-term overall survival results among patients with de Novo HER2-positive metastatic breast cancer.
Results from a real-world, population-based study demonstrated that broader use of HER2-targeted systemic therapies significantly improved long-term overall survival results among patients with de Novo HER2-positive metastatic breast cancer.
Results from a real-world,...
07/08/2025
Oncology
News
Real-World Treatment Patterns, Outcomes of Patients With HER2-Low Metastatic Breast Cancer
06/24/2025
Allison Casey
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
A retrospective study found that...
06/24/2025
Oncology
Conference Coverage
Trastuzumab Plus Gedatolisib Demonstrates Promising Efficacy, Safety Among Patients With HER2-Positive Metastatic Breast Cancer
06/23/2025
Stephanie Holland
According to results from the phase 2 KM-10A/KCSG BR18-13 study, trastuzumab plus gedatolisib demonstrated promising efficacy and safety among patients with HER2-positive metastatic breast cancer.
According to results from the phase 2 KM-10A/KCSG BR18-13 study, trastuzumab plus gedatolisib demonstrated promising efficacy and safety among patients with HER2-positive metastatic breast cancer.
According to results from the...
06/23/2025
Oncology
Conference Coverage
Omission of Carboplatin from Neoadjuvant Therapy Demonstrates Promise for Patients With HER2-Positive Early Breast Cancer
06/10/2025
Stephanie Holland
According to results from the phase 3 neoCARHP trial, de-escalated neoadjuvant taxane therapy plus trastuzumab and pertuzumab without the addition of carboplatin demonstrated promise in HER2-positive early breast cancer.
According to results from the phase 3 neoCARHP trial, de-escalated neoadjuvant taxane therapy plus trastuzumab and pertuzumab without the addition of carboplatin demonstrated promise in HER2-positive early breast cancer.
According to results from the...
06/10/2025
Oncology
Conference Coverage
Pertuzumab Plus Trastuzumab and Chemotherapy for Patients With HER2-Positive Early Breast Cancer
05/20/2025
Stephanie Holland
According to final results from the phase 3 APHINITY trial, the addition of adjuvant pertuzumab to trastuzumab and chemotherapy improved outcomes among patients with operable HER2-positive early breast cancer.
According to final results from the phase 3 APHINITY trial, the addition of adjuvant pertuzumab to trastuzumab and chemotherapy improved outcomes among patients with operable HER2-positive early breast cancer.
According to final results from...
05/20/2025
Oncology
News
Zanidatamab Plus Palbociclib and Fulvestrant Demonstrates Promise in HR-Positive, HER2-Positive Metastatic Breast Cancer
05/09/2025
Stephanie Holland
According to results from a phase 2a study, zanidatamab plus palbociclib and fulvestrant demonstrated promising efficacy and safety among previously treated patients with HR-positive, HER2-positive unresectable or metastatic breast cancer.
According to results from a phase 2a study, zanidatamab plus palbociclib and fulvestrant demonstrated promising efficacy and safety among previously treated patients with HR-positive, HER2-positive unresectable or metastatic breast cancer.
According to results from a...
05/09/2025
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use